Latham & Watkins advised NextGen Healthcare, Goodwin Procter advised Thoma Bravo, and Skadden advised Morgan Stanley & Co. LLC as financial advisor to NextGen Healthcare on...
Thoma Bravo’s Acquisition of NextGen Healthcare
LG Chem’s Acquisition of AVEO Oncology
Latham & Watkins LLP represented LG Chem in the transaction, while WilmerHale LLP represented AVEO. LG Chem, Ltd. (KOSPI: 051910) entered into a definitive agreement to acquire...
Ligand’s Spin-off of OmniAb Business
Latham & Watkins represented Ligand in the transaction, while Weil, Gotshal & Manges represented APAC. Ligand Pharmaceuticals Incorporated has announced the signing of a definitive merger...
P3 Health Partners’ Business Combination with Foresight Acquisition Corp.
Latham & Watkins represented P3 Health Partners in the transaction. P3 Health Partners, a patient-centered and physician-led population health management company, has closed its previously announced business combination...
Minerva Surgical’s $75 Million Initial Public Offering
Latham & Watkins represented the underwriters in the transaction. Minerva Surgical, Inc. (Minerva Surgical), a women’s health company focused on the treatment of Abnormal Uterine Bleeding (AUB),...